Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AmerisourceBergen Oncology Drug Repackaging Program Draws $260m Fine

Executive Summary

Now-defunct AmerisourceBergen subsidiary inappropriately repackaged oncology support drugs like Neupogen and Procrit in pre-filled syringes, violating the law and prompting safety concerns, Department of Justice announced.

You may also be interested in...



AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay

Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.

FDA Works To Encourage Office-Use Compounding In Advance Of Legislation

FDA looks to carve out a place for office-use compounding within Section 503B, the new framework created after deadly fungal contamination of products, while industry supports efforts in Congress to allow it under the traditional Section 503A.

Curbing Cancer Drug Costs: Lartruvo Vial Sizes Designed To Reduce Waste

Lilly researchers used real-world data to identify a second vial size for Lartruvo that could reduce waste by nearly 87% compared to offering only a single large-size vial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel